Differences in Vessel Healing Between Sirolimus- and Everolimus-Eluting Stent Implantation for Bifurcation Lesions: The J-REVERSE Optical Coherence Tomography Substudy

Can J Cardiol. 2016 Mar;32(3):384-90. doi: 10.1016/j.cjca.2015.06.029. Epub 2015 Jul 6.

Abstract

Background: We aimed to clarify the differences in vessel healing after stenting of bifurcation lesions using sirolimus-eluting stents (SESs) or everolimus-eluting stents (EESs).

Methods: Japanese Registry Study in Comparison Between Everolimus-Eluting Stent and Sirolimus-Eluting Stent for the Bifurcation Lesion (J-REVERSE) is a prospective multicentre registry of 303 bifurcation lesions that were treated with provisional SES or EES with or without final kissing inflation. The first 115 lesions at selected study sites were predefined for inclusion in the optical coherence tomography (OCT) substudy, and 9-month follow-up OCT was conducted in 64 lesions (SES, n = 18; EES, n = 46). In addition to standard OCT parameters, stent eccentricity index (SEI; minimum divided by the maximum stent diameter), neointimal unevenness score (NUS; maximum neointimal thickness in the cross-section [CS] divided by the average neointimal thickness [NIT] of the same CS; uniformity of the neointima suppression) were averaged for each segment (proximal, bifurcation, and distal segments).

Results: Overall, the average stent and luminal area, NIT, and frequency of uncovered struts were similar. The frequency of malapposed struts and SEI were significantly lower in the EES group than in the SES group. The EES group had a significantly smaller NUS in the proximal and distal segments.

Conclusions: EESs offer homogeneous vessel healing with less malapposition in the treatment of bifurcation lesions.

Publication types

  • Multicenter Study

MeSH terms

  • Aged
  • Coronary Artery Disease / diagnosis
  • Coronary Artery Disease / surgery*
  • Coronary Vessels / pathology*
  • Coronary Vessels / surgery
  • Drug-Eluting Stents*
  • Everolimus / pharmacology*
  • Female
  • Follow-Up Studies
  • Humans
  • Immunosuppressive Agents / pharmacology
  • Male
  • Prospective Studies
  • Prosthesis Design
  • Registries*
  • Sirolimus / pharmacology*
  • Time Factors
  • Tomography, Optical Coherence / methods*

Substances

  • Immunosuppressive Agents
  • Everolimus
  • Sirolimus